Cooley advised Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel small molecule precision medicines, on its agreement to be acquired by Jazz Pharmaceuticals for $820 million upfront payment and up to $500 million in potential approval and sales milestones.
Actio Biosciences to Be Acquired by Jazz Pharmaceuticals for Up to $1.32 Billion